200 results on '"Okano, Susumu"'
Search Results
2. Immunotherapy for head and neck cancer: Fundamentals and therapeutic development
3. Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
4. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
5. Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer
6. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
7. Significance of imaging-detected extranodal extension (iENE) in locally advanced head and neck squamous cell carcinoma (LASCCHN) treated with induction chemotherapy followed by chemoradiotherapy.
8. Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma
9. Effectiveness of an online support program to help female cancer patients manage their health and illness: Protocol for a randomized controlled trial
10. Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study
11. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
12. A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma
13. New Treatment Development for Larynx Preservation
14. Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
15. O9-2 Salvage chemotherapy with paclitaxel plus cetuximab (PE)-based regimen following immune checkpoint inhibitor in R/M SCCHN
16. MO43-1 The treatment sequence of weekly paclitaxel, carboplatin, and cetuximab (PCE) followed by nivolumab for R/M SCCHN
17. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology
18. Long‐term outcomes of patients with oral cavity cancer receiving postoperative radiotherapy after salvage neck dissection for cervical lymph node recurrence.
19. Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study.
20. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
21. A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer
22. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer
23. Proton beam therapy for olfactory neuroblastoma
24. Association between baseline blood pressure and the incidence of lenvatinib‐induced hypertension in patients with thyroid cancer.
25. Grade 3 infusion-related reaction because of cetuximab administered with 5-fluorouracil and cisplatin chemotherapy for a recurrent and metastatic head and neck cancer patient who received chlorpheniramine 5 mg, dexamethasone 13.2 mg, and aprepitant 125 mg premedication
26. Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study
27. Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer
28. Recurrent or Metastatic HNSCC: Systemic Therapy
29. Gemcitabine monotherapy in patients with heavily treated nasopharyngeal cancer: a case series
30. Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
31. O2-5 Impact of proton pump inhibitors and antibiotics on efficacy of nivolumab in patients with R/M HNSCC
32. P51-8 Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer
33. O2-6 Salvage local therapy for the progressive lesion after nivolumab in the patients with R/M SCCHN
34. Human papillomavirus-related oropharyngeal carcinoma
35. Systemic therapy for salivary gland malignancy: current status and future perspectives
36. MO8-5 Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer
37. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck
38. Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
39. Phase II Feasibility Trial of Adjuvant Chemoradiotherapy with 3-weekly Cisplatin for Japanese Patients with Post-operative High-risk Squamous Cell Carcinoma of the Head and Neck
40. Induction Chemotherapy with Docetaxel, Cisplatin and S-1 Followed by Proton Beam Therapy Concurrent with Cisplatin in Patients with T4b Nasal and Sinonasal Malignancies
41. Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
42. Fixed drug eruption dramatically exacerbated during treatment with programmed death 1 inhibitor
43. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
44. Phase 1 study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma
45. Efficacy of nivolumab for head and neck cancer arising from subsites which were not included in CheckMate 141
46. A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
47. Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
48. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
49. Immunotherapy for squamous cell carcinoma of the head and neck.
50. Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.